0000000000037635

AUTHOR

Lothar Färber

showing 6 related works from this author

Immunomodulatory and Hematopoietic Effects of Recombinant Human Interleukin-6 in Patients with Advanced Renal Cell Cancer

1996

Interleukin-6 (IL-6) is a cytokine with pleiotropic biologic activities on B cells, T cells, and hematopoietic progenitors. The present study was undertaken to assess pharmacodynamic effects of subcutaneous administration of IL-6 on blood counts, immunologic parameters, and acute-phase reactants. Blood samples were taken from patients with advanced renal cell cancer participating in a phase II trial of recombinant human IL-6. Multiparameter FACS analyses of peripheral blood mononuclear cells were performed using antibodies against CD3, CD4, CD8, HLA-DR, CD56, CD28, CD38, CD19, sIgM, and sIgG. Serum levels of IL-10, soluble CD23 (sCD23), sCD25, IL-1 receptor antagonist protein (IL-1RA), solu…

medicine.medical_specialtyInjections Subcutaneousmedicine.medical_treatmentImmunologyPeripheral blood mononuclear cellCD19chemistry.chemical_compoundImmunophenotypingAdjuvants ImmunologicVirologyInternal medicinemedicineHumansAcute-Phase ReactionCarcinoma Renal CellbiologyInterleukin-6business.industryCD23NeopterinCell BiologyKidney NeoplasmsRecombinant ProteinsBlood Cell CountHematopoiesisHaematopoiesisCytokineEndocrinologychemistryImmunologybiology.proteinbusinessCD8Journal of Interferon & Cytokine Research
researchProduct

IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-p)

1993

Experimental animal and human in vivo studies have previously demonstrated the impact of exogenous administration of various cytokines on frequencies of circulating myeloid and LAK precursor cells. For the first time we investigated whether exogenous cytokines, in the absence of antigenic challenge, may also influence frequencies of circulating antigen-specific cytotoxic T-lymphocyte precursor cells. We further asked whether triggering of autoimmune pathways as has been reported for several cytokines can be confirmed on the cellular level by demonstration of induction of autoreactive CTL-p. Limiting dilution analysis was used to determine alloreactive CTL-p frequencies in 31 patients with n…

Interleukin 2Stem Cellsmedicine.medical_treatmentClone (cell biology)Autoimmunityhemic and immune systemschemical and pharmacologic phenomenaHematologyGeneral MedicineBiologyRecombinant ProteinsInterferon-gammaCTL*CytokineImmunologymedicineSystemic administrationHumansInterleukin-2Cytotoxic T cellInterleukin-3Interferon gammaT-Lymphocytes CytotoxicInterleukin 3medicine.drugAnnals of Hematology
researchProduct

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patie…

1998

Extensive pretreatment has been identified as a significant risk factor for failure of sufficient PBSC mobilization. From published data and our own experience we defined pretreatment variables which render patients at risk for not collecting at least 2.5 x 10(6) CD34-positive cells per kg bodyweight (BW). These variables were previous unsuccessful PBSC mobilization trial, previous large field radiotherapy, four or more cycles of myelosuppressive chemotherapy regimens, and combinations of extended field radiotherapy plus chemotherapy. Based on these inclusion criteria we treated 19 patients with disease-specific conventional-dose chemotherapy followed by sequential subcutaneous administrati…

AdultMalemedicine.medical_specialtyNeutropeniaFevermedicine.medical_treatmentPainSalvage therapyGastroenterologyTesticular NeoplasmsRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansMultiple myelomaTesticular cancerSalvage TherapyTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationDrug SynergismHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyHematopoietic Stem Cell MobilizationBlood Cell CountSeminomaSurgeryGranulocyte colony-stimulating factorLymphomaRegimenHematologic NeoplasmsFemaleInterleukin-3GerminomabusinessBone Marrow Transplantation
researchProduct

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study.

1998

The present phase II study was undertaken to assess antitumoral activity, safety and tolerability of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 micrograms/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchAntineoplastic AgentsGastroenterologySubcutaneous injectionInternal medicinemedicineHumansTreatment FailureCarcinoma Renal CellAgedKidneyThrombocytosisbusiness.industryInterleukin-6CancerImmunotherapyMiddle Agedmedicine.diseaseKidney NeoplasmsRecombinant Proteinsmedicine.anatomical_structureC-Reactive ProteinOncologyTolerabilityImmunologyFemalebusinessKidney diseaseEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo

1996

The present study was designed to investigate in vivo immunomodulatory properties of hematopoietic growth factors. The influence on the activation of cytokine synthesis and on the expression of surface antigens associated with cellular activation of G-CSF or GM-CSF was investigated in cancer patients receiving these factors. One single dose of growth factor was administered to patients with bladder cancer (G-CSF group) or small cell lung cancer (GM-CSF group) before chemotherapy. After cytoreductive chemotherapy patients received supportive therapy with G-CSF or GM-CSF. Peripheral blood mononuclear cells and plasma samples were obtained for flow cytometry, Northern blot analysis, and assess…

AdultSialoglycoproteinsmedicine.medical_treatmentBiologyPeripheral blood mononuclear cellAdjuvants ImmunologicGranulocyte Colony-Stimulating FactormedicineHumansRNA MessengerGrowth SubstancesInterleukin 6AgedInterleukin-6MonocyteGrowth factorInterleukin-8Granulocyte-Macrophage Colony-Stimulating FactorReceptors Interleukin-1Receptors Interleukin-2HematologyGeneral MedicineMiddle AgedHematopoietic Stem CellsRecombinant ProteinsGranulocyte colony-stimulating factorInterleukin 1 Receptor Antagonist ProteinHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureCytokineSolubilityAntigens SurfaceImmunologyCancer researchbiology.proteinmedicine.drugAnnals of Hematology
researchProduct